Bioeletric Stimulation in Patients With Chronic Kidney Failure
Bioelectric Stimulation to Improve Kidney Function and Sarcopenia in Patients on Hemodialysis: Randomized Controlled Trial
1 other identifier
interventional
20
0 countries
N/A
Brief Summary
This study aims to evaluate the effects of electrical stimulation on renal function and physical capacity in patients with chronic kidney disease (CKD). This is a randomized controlled trial with patients from the HD outpatient of Santa Clara hospital at Irmandade Santa Casa de Misericórdia de Porto Alegre (ISCMPA), who will be allocated to a control group (it will be evaluated and reassessed) or intervention group (it will receive electrical stimulation). Interventions will occur during the HD session, twice a week, for eight weeks, totaling 16 sessions. The groups will be evaluated prior to physiotherapy intervention and at the end. The following outcomes will be measured: renal function, functional capacity, muscle strength of lower limbs and quality of life.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Nov 2020
Shorter than P25 for not_applicable
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 23, 2020
CompletedFirst Posted
Study publicly available on registry
October 29, 2020
CompletedStudy Start
First participant enrolled
November 1, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 28, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
April 30, 2021
CompletedNovember 2, 2020
October 1, 2020
4 months
October 23, 2020
October 29, 2020
Conditions
Outcome Measures
Primary Outcomes (2)
Change in soluble α-Klotho protein expression.
It will be assessed by the analysis of the plasma content by immunoassay assay (ELISA).
Baseline, after 4 weeks and after 8 weeks.
Change in serum creatinine.
It will be assessed by the analysis of the plasma content by spectrophotometry.
Baseline, after 4 weeks and after 8 weeks.
Secondary Outcomes (4)
Functional capacity.
Baseline and after 8 weeks.
Muscle strength of lower limbs.
Baseline and after 8 weeks.
Muscle strength of quadriceps.
Evaluated: baseline and after 8 weeks.
Quality of life evaluation.
Baseline and after 8 weeks.
Study Arms (2)
Electrical stimulation
EXPERIMENTALThe patients will receive neuromuscular electrical stimulation on quadriceps muscle and sensory stimulation in the anatomical region of the kidneys.
Control
NO INTERVENTIONThe patients only will be evaluated and reassessed.
Interventions
A protocol of neuromuscular electrical stimulation will be applied on the quadriceps muscle (symmetric biphasic pulsed current, 80 Hz, 400 µs, 10 s contraction time, 50s/30s/20s rest time, the reciprocal mode, 20 min. After, a protocol of sensory stimulation will be applied on the anatomical region of the kidneys (First: 50 pps, 300 µs, continuous mode for 5 min; Second: 30 pps, 100 µs, continuous mode for 10 min; Third: 20 pps, 1000 µs for 30 min).
Eligibility Criteria
You may qualify if:
- Patients with CKF on HD for a period ≥ 3 months;
- Kt/V ≥ 1.2 or URR ≥ 65%
- Age between 18 and 80 years old;
- Functional capacity ≥ 300 meters in the 6MWT.
You may not qualify if:
- Cognitive dysfunction that prevents the performance of evaluations, as well as an inability to understand and sign the informed consent form;
- Intolerance to the electrostimulator and/or alteration of skin sensitivity;
- Patients with sequelae of stroke;
- Recent acute myocardial infarction (two months);
- Uncontrolled hypertension (SBP\> 230 mmHg and DBP\> 120 mmHg);
- Grade IV heart failure according to the New York Heart Association or decompensated;
- Unstable angina;
- Peripheral vascular changes in the lower limbs such as deep vein thrombosis;
- Disabling osteoarticular or musculoskeletal disease;
- Uncontrolled diabetes (blood glucose\> 300mg/dL);
- Feverish state and/or active infectious disease.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Rodrigo DM Plentz, PhD
Federal University of Health Sciences of Porto Alegre
Central Study Contacts
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- SINGLE
- Who Masked
- OUTCOMES ASSESSOR
- Purpose
- TREATMENT
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
October 23, 2020
First Posted
October 29, 2020
Study Start
November 1, 2020
Primary Completion
February 28, 2021
Study Completion
April 30, 2021
Last Updated
November 2, 2020
Record last verified: 2020-10
Data Sharing
- IPD Sharing
- Will not share